NCT01330628

Brief Summary

The purpose of the study is to evaluate the safety and efficacy of laser atherectomy with balloon angioplasty compared to balloon angioplasty alone in the treatment of above the knee peripheral artery in-stent restenosis.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
252

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jun 2011

Typical duration for phase_2

Geographic Reach
2 countries

34 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 4, 2011

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 7, 2011

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2011

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2014

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

June 15, 2016

Completed
Last Updated

August 18, 2016

Status Verified

July 1, 2016

Enrollment Period

2.8 years

First QC Date

April 4, 2011

Results QC Date

May 4, 2016

Last Update Submit

July 19, 2016

Conditions

Keywords

peripheral arterial diseasein stent restenosisperipheral vascular disease

Outcome Measures

Primary Outcomes (2)

  • Freedom From Target Lesion Revascularization (TLR)

    Number of participants free from Target Lesion Revascularization (TLR) through 6 months follow-up.

    6 months

  • Freedom From Major Adverse Events (MAE)

    Number of participants free from Major Adverse Events (MAE) at 30 days. MAE are defined all cause death, major amputation in the target limb, or target lesion revascularization (TLR) from procedure to 30 days (±7 days).

    30 days

Study Arms (2)

Laser atherectomy and PTA

EXPERIMENTAL

laser, then balloon angioplasty

Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters

Balloon angioplasty

ACTIVE COMPARATOR
Procedure: Balloon angioplasty

Interventions

application of laser energy to remove blockage followed by standard balloon angioplasty

Laser atherectomy and PTA

standard balloon catheters for PTA

Balloon angioplasty

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • PAD with Rutherford class 1-4
  • Resting ABI \<0.9 or abnormal exercise ABI \<0.9
  • History of previous femoropopliteal nitinol stenting
  • Angiographic significant restenosis (\>=50%)
  • Target lesion length \>=4 cm; no more than 3 cm outside stent at either end
  • Vessel diameter \>=5 mm and \<=7 mm
  • At least one widely patent tibial or peroneal artery to the foot

You may not qualify if:

  • Patient is pregnant or breast feeding
  • Evidence of acute limb ischemia
  • Life expectancy \<12 months
  • CVA within 60 days of screening
  • Myocardial infarction within 60 days of procedure
  • Known allergy to contract media
  • Known contraindication to aspirin, antiplatelet and anti-coagulation therapies
  • Uncontrolled hypercoagulability
  • Present or suspected systemic infection in target limb
  • Serum creatinine \>= 2.5 mg/dl unless dialysis dependent
  • Previous treatment to target vessel within 3 months of study procedure
  • Drug eluting stents or covered stents in target lesion
  • Ipsilateral and/or contralateral iliac stenosis \>= 50% DS that is not successfully treated prior to index procedure or with final residual stenosis \<= 30% documented by angiography
  • Planned or predicted cardiovascular surgical or interventional procedures prior to completion of the 30-day follow-up
  • Identification of any lesion below the target stent in the treated leg \>50% that will require preplanned or predicted treatment within 30 days(prior to the 6 month follow up)
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (34)

St. Vincent's East

Birmingham, Alabama, 35235, United States

Location

Thomas Hospital

Fairhope, Alabama, 36533, United States

Location

St. Vincent Heart Clinic Arkansas

Little Rock, Arkansas, 72205, United States

Location

Arkansas Heart Hospital

Little Rock, Arkansas, 72211, United States

Location

UC-Davis Medical Centers

Sacramento, California, 95817, United States

Location

Yale - New Haven Hospital

New Haven, Connecticut, 06510, United States

Location

Washington Hospital Center

Washington D.C., District of Columbia, 20010, United States

Location

The Cardiac and Vascular Institute

Gainesville, Florida, 32605, United States

Location

Memorial Regional Hospital

Hollywood, Florida, 33021, United States

Location

Mount Sinai Medical Center

Miami, Florida, 33140, United States

Location

St. John's Hospital

Springfield, Illinois, 62874, United States

Location

Community Hospital

Munster, Indiana, 46321, United States

Location

Genesis Health System

Davenport, Iowa, 52803, United States

Location

Cardiovascular Consultants

Bossier City, Louisiana, 71111, United States

Location

Regional Medical center of Acadiana

Lafayette, Louisiana, 70506, United States

Location

Opelousas General Hospital

Opelousas, Louisiana, 70570, United States

Location

Steward - St. Elizabeth's

Boston, Massachusetts, 02135, United States

Location

St. John's - Providence Hospital

Southfield, Michigan, 48075, United States

Location

Metro Health Hospital

Wyoming, Michigan, 49519, United States

Location

Hattiesburg Clinic

Hattiesburg, Mississippi, 39401, United States

Location

Deborah Heart and Lung

Browns Mills, New Jersey, 08015, United States

Location

New York University

New York, New York, 10016, United States

Location

Coastal Surgery Specialists

Wilmington, North Carolina, 284001, United States

Location

Bryn Mawr

Bryn Mawr, Pennsylvania, 19010, United States

Location

The Miriam Hospital

Providence, Rhode Island, 02904, United States

Location

Wellmont Holston Valley Medical

Kingsport, Tennessee, 37660, United States

Location

Presbyterian Hospital of Dallas

Dallas, Texas, 75230, United States

Location

El Paso Cardiac and Endovascular Center

El Paso, Texas, 79902, United States

Location

Tyler Cardiac and Endovascular Center

Tyler, Texas, 75701, United States

Location

Providence Health Center

Waco, Texas, 76712, United States

Location

Sentara Norfolk General Hospital

Norfolk, Virginia, 23507, United States

Location

Wheaton Franciscan Healthcare - All Saints Hospital

Milwaukee, Wisconsin, 53212, United States

Location

St. Luke's Medical Center

Milwaukee, Wisconsin, 53215, United States

Location

Transcatheter Medical Inc.

San Juan, 00926, Puerto Rico

Location

Related Publications (1)

  • Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, Mena-Hurtado C, Beasley R, Soukas P, Colon-Hernandez PJ, Stark MA, Walker C; EXCITE ISR Investigators. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):92-101. doi: 10.1016/j.jcin.2014.09.009. Epub 2014 Dec 10.

MeSH Terms

Conditions

Peripheral Arterial DiseasePeripheral Vascular Diseases

Interventions

Angioplasty, Balloon

Condition Hierarchy (Ancestors)

AtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

AngioplastyCatheterizationTherapeuticsEndovascular ProceduresVascular Surgical ProceduresCardiovascular Surgical ProceduresSurgical Procedures, OperativeMinimally Invasive Surgical ProceduresInvestigative Techniques

Results Point of Contact

Title
Amanda Johnson, VP of Regulatory & Medical Affairs
Organization
Spectranetics

Study Officials

  • Eric J Dippel, MD

    Genesis Health System

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2011

First Posted

April 7, 2011

Study Start

June 1, 2011

Primary Completion

March 1, 2014

Study Completion

May 1, 2015

Last Updated

August 18, 2016

Results First Posted

June 15, 2016

Record last verified: 2016-07

Locations